1. Nivolumab for malignant transformation of ovarian mature cystic teratoma
- Author
-
70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, 80378736, 00335283, 40360698, Yoshimura, Kayoko, Yamanoi, Koji, Kanai, Masashi, Okunomiya, Asuka, Sagae, Yusuke, Sunada, Masumi, Taki, Mana, Ukita, Masayo, Chigusa, Yoshitsugu, Horie, Akihito, Yamaguchi, Ken, Hamanishi, Junzo, Minamiguchi, Sachiko, Yamamoto, Noboru, Muto, Manabu, Mandai, Masaki, 70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, 80378736, 00335283, 40360698, Yoshimura, Kayoko, Yamanoi, Koji, Kanai, Masashi, Okunomiya, Asuka, Sagae, Yusuke, Sunada, Masumi, Taki, Mana, Ukita, Masayo, Chigusa, Yoshitsugu, Horie, Akihito, Yamaguchi, Ken, Hamanishi, Junzo, Minamiguchi, Sachiko, Yamamoto, Noboru, Muto, Manabu, and Mandai, Masaki
- Abstract
Mature cystic teratoma of the ovary (MCT) occasionally undergoes malignant transformation (MT) that is resistant to chemotherapy and has a poor prognosis. We experienced a case of clinically aggressive MCT-MT that invades surrounding organs and tissues. Although tumor was resected entirely, a rapid tumor recurrence occurred during postoperative chemotherapy (paclitaxel + ifosfamide + cisplatin). The results of comprehensive genomic profiling test performed early in the postoperative period showed a high tumor mutational burden of 23 mutations/Mb. Treatment with nivolumab monotherapy has promptly been initiated and has been very successful for more than one year.
- Published
- 2022